[2-(3-tert-butylsulfanyl-pyridin-2-ylmethylsulfanyl)-ethyl]carbamic acid tert-butyl ester | 331780-05-3

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: [2-(3-tert-butylsulfanyl-pyridin-2-ylmethylsulfanyl)-ethyl]carbamic acid tert-butyl ester
• 英文别名: tert-butyl 2-((3-(tert-butylthio)pyridin-2-yl)methylthio)ethylcarbamate；3-t-Butylthio-2-(2-t-butoxycarbonylaminoethylthiomethyl)-pyridine；tert-butyl N-[2-[(3-tert-butylsulfanylpyridin-2-yl)methylsulfanyl]ethyl]carbamate
• CAS: 331780-05-3
• 化学式: C₁₇H₂₈N₂O₂S₂
• 分子量: 356.554
• InChiKey: YLPFZJGWWMRTDL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  23
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  102
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  [2-(3-tert-butylsulfanyl-pyridin-2-ylmethylsulfanyl)-ethyl]carbamic acid tert-butyl ester 以 盐酸 、 重水 为溶剂， 生成 2-(2-amino-ethylsulfanylmethyl)-pyridine-3-thiol dihydrochloride
  参考文献：
  名称：

  7-acylamino-3-heteroarylthio-3-cephem carboxylic acid antibiotics and prodrugs thereof

  摘要：

  本发明涉及具有III式或IV式的头孢菌素前药：或其药用可接受的盐，其中R′1选自由氢和—C(O)CH(NH2)CH3的群组，R′2选自由氢和在哺乳动物中发现的一种酶可水解的酰基团，但条件是当R′1或R′2中的一个是氢时，另一个不是。A、B、L、G、E和J分别独立地为氮或碳，使得相应的环被选自的群组选中，前提是群组—CH2—S—CH2CH2NHR′2仅连接到所述杂环基团的一个碳原子上，Q选自氮和—CX的群组，其中X选自氢和氯。

  公开号：

  US06723716B1
• 作为产物：
  描述：

  3-(叔丁基硫代)吡啶-2-羧酸 在 氯化亚砜 、 氯甲酸乙酯 、 三乙胺 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 为溶剂， 反应 17.0h， 生成 [2-(3-tert-butylsulfanyl-pyridin-2-ylmethylsulfanyl)-ethyl]carbamic acid tert-butyl ester
  参考文献：
  名称：

  Relationships between structure, antibacterial activity, serum stability, pharmacokinetics and efficacy in 3-(heteroarylthio)cephems. Discovery of RWJ-333441 (MC-04,546)

  摘要：

  SAR studies in a series of related 3-(heteroarylthio)cephems determined that a relatively high chemical reactivity of the beta-lactam ring, modulated by electronic effects of substituents at C-3 and C-7, is necessary to achieve high in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA). Such high reactivity results in lowered hydrolytic stability and concomitantly increases susceptibility to beta-lactam ring opening mediated by serum enzymes. Therefore, optimization of anti-MRSA activity versus stability toward serum-mediated degradation required a fine balance of substituent effects. Serum stability studies (measured as percentage of parent drug degraded after 60 min incubation) revealed up to 80-fold difference in degradation rate in a series of closely related (3-heteroarylthio)cephems. Of the compounds evaluated, RWJ-333441 (MC-04,546) possessed the best balance of serum stability (6% degradation after 60 min incubation) and in vitro activity versus MRSA (S. aureus COL MIC-I mug/mL). Accordingly, RWJ-333441 displayed excellent in vivo efficacy versus methicillin-susceptible Staphylococcus aureus (MSSA, ED50=0.39 mg/kg in mouse sepsis model with S. aureus Smith) and good pharmacokinetic properties in the rat (Cl-total=0.39 L/h/kg). (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(02)00431-5

文献信息

• [EN] CARBACEPHEM ß-LACTAM ANTIBIOTICS<br/>[FR] ANTIBIOTIQUES BÊTA-LACTAMES À CARBACÉPHÈME
  申请人：ACHAOGEN INC

  公开号：WO2009055696A1

  公开（公告）日：2009-04-30

  Carbacephem β-lactam antibiotics having the following chemical structures (I) and (II) are disclosed, including stereoisomers, pharmaceutically acceptable salts, esters and prodrugs thereof, wherein Ar2, R1, R2 and R3 are as defined herein. The compounds are useful for the treatment of bacterial infections, in particular those caused by methicillin-resistant Staphylococcus spp.

  Carbacephem β-内酰胺抗生素具有以下化学结构（I）和（II），包括立体异构体、药用可接受的盐、酯和前药，其中Ar2、R1、R2和R3如本文所定义。这些化合物可用于治疗细菌感染，特别是由耐甲氧西林葡萄球菌属引起的感染。
• 7-acylamino-3-heteroarylthio-3-cephem carboxylic acid antibiotics and prodrugs thereof
  申请人：Essential Therapeutics, Inc.

  公开号：US06723716B1

  公开（公告）日：2004-04-20

  The present invention relates to a cephem prodrug having formula III or formula IV: or a pharmaceutically acceptable salt thereof, wherein R′1 is selected from the group consisting of hydrogen and —C(O)CH(NH2)CH3 and R′2 is selected from the group consisting of hydrogen and an acyl group that is cleaved by an enzyme found in mammals, with the proviso that, when either R′1 or R′2 is hydrogen, the other is not. A, B, L, G, E, and J are each independently nitrogen or carbon such that the respective rings are selected from the group consisting of provided that the group —CH2—S—CH2CH2NHR′2 is attached only to a carbon atom of said heterocyclic group, and Q is selected from the group consisting of nitrogen and —CX, wherein X is selected from the group consisting of hydrogen and chlorine.

  本发明涉及具有III式或IV式的头孢菌素前药：或其药用可接受的盐，其中R′1选自由氢和—C(O)CH(NH2)CH3的群组，R′2选自由氢和在哺乳动物中发现的一种酶可水解的酰基团，但条件是当R′1或R′2中的一个是氢时，另一个不是。A、B、L、G、E和J分别独立地为氮或碳，使得相应的环被选自的群组选中，前提是群组—CH2—S—CH2CH2NHR′2仅连接到所述杂环基团的一个碳原子上，Q选自氮和—CX的群组，其中X选自氢和氯。
• [EN] CARBACEPHEM ß-LACTAM ANTIBIOTICS<br/>[FR] ANTIBIOTIQUES DE TYPE ?-LACTAME À BASE DE CARBACÉPHÈME
  申请人：ACHAOGEN INC

  公开号：WO2010030811A3

  公开（公告）日：2010-08-12
• 7-ACYLAMINO-3-HETEROARYLTHIO-3-CEPHEM CARBOXYLIC ACID ANTIBIOTICS AND PRODRUGS THEREOF
  申请人：Trine Pharmaceuticals, Inc.

  公开号：EP1222194B1

  公开（公告）日：2005-06-15
• CARBACEPHEM ß -LACTAM ANTIBIOTICS
  申请人：Achaogen, Inc.

  公开号：EP2205600A1

  公开（公告）日：2010-07-14